Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24148
Title: | Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma | Authors: | Marcq, Elly Siozopoulou, Vasiliki De Waele, Jorrit van Audenaerde, Jonas Zwaenepoel, Karen SANTERMANS, Eva HENS, Niel Pauwels, Patrick van Meerbeeck, Jan P. Smits, Evelien L. J. |
Issue Date: | 2017 | Publisher: | TAYLOR & FRANCIS INC | Source: | ONCOIMMUNOLOGY, 6(1), p. 1-11 (Art N° e1261241) | Abstract: | Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis and an increasing incidence, for which novel therapeutic strategies are urgently required. Since the immune system has been described to play a presumed role in the protection against MPM, characterization of its tumor immune microenvironment (TME) and immune checkpoints can identify new immunotherapeutic targets and their predictive and/or prognostic value. To characterize the TME and the immune checkpoint expression profile, we performed immunohistochemistry (IHC) on formalin-fixed paraffin embedded (FFPE) tissue sections from 54 MPM patients (40 at time of diagnosis; 14 treated with chemotherapy). We stained for PD-1, PD-L1, TIM-3, LAG-3, CD4, CD8, CD45RO, granzyme B, FoxP3 and CD68. Furthermore, we analyzed the relationship between the immunological parameters and survival, as well as response to chemotherapy. We found that TIM-3, PD-1 and PD-L1 were expressed on both immune and tumor cells. Strikingly, PD-1 and PD-L1 expression on tumor cells was only seen in unpretreated samples. No LAG-3 expression was observed. CD45RO expression in the stroma was an independent negative predictive factor for response on chemotherapy, while CD4 and TIM-3 expression in lymphoid aggregates were independent prognostic factors for better outcome. Our data propose TIM-3 as a promising new target in mesothelioma. Chemotherapy influences the expression of immune checkpoints and therefore further research on the best combination treatment schedule is required. | Notes: | [Marcq, Elly; Siozopoulou, Vasiliki; De Waele, Jorrit; van Audenaerde, Jonas; Zwaenepoel, Karen; Pauwels, Patrick; van Meerbeeck, Jan P.; Smits, Evelien L. J.] Univ Antwerp, Ctr Oncol Res, Antwerp, Belgium. [Siozopoulou, Vasiliki; Zwaenepoel, Karen; Pauwels, Patrick] Univ Antwerp Hosp, Dept Pathol, Antwerp, Belgium. [Santermans, Eva; Hens, Niel] Hasselt Univ, Interunivers Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium. [Hens, Niel] Univ Antwerp, Vaccine & Infect Dis Inst, Ctr Hlth Econ Res & Modeling Infect Dis, Antwerp, Belgium. [van Meerbeeck, Jan P.] Univ Antwerp Hosp, MOCA, Thorac Oncol, Antwerp, Belgium. [Smits, Evelien L. J.] Univ Antwerp, Vaccine & Infect Dis Inst, Lab Expt Hematol, Antwerp, Belgium. | Keywords: | biomarkers; immune checkpoints; immunohistochemistry; mesothelioma; tumor microenvironment;Biomarkers; immune checkpoints; immunohistochemistry; mesothelioma; tumor microenvironment | Document URI: | http://hdl.handle.net/1942/24148 | ISSN: | 2162-402X | e-ISSN: | 2162-402X | DOI: | 10.1080/2162402X.2016.1261241 | ISI #: | 000397069400023 | Rights: | © 2017 Taylor & Francis Group, LLC | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2018 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
marcq2016.pdf Restricted Access | Published version | 1.61 MB | Adobe PDF | View/Open Request a copy |
Revised Manuscript_2016ONCOIMM0498.pdf | Peer-reviewed author version | 892.66 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
24
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
66
checked on Apr 30, 2024
Page view(s)
58
checked on Sep 5, 2022
Download(s)
104
checked on Sep 5, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.